bispecific antibody
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
Pfizer announces phase 3 results for potential non-small cell lung cancer treatment
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival
MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults
Approximately 43,000 people are diagnosed with lung cancer every year in the UK
BMS shares overall survival results for Opdivo in phase 3 lung cancer trial
More than 200,000 people are diagnosed with lung cancer in the US every year
J&J’s Rybrevant combination approved by FDA to treat EGFR-mutated NSCLC
Alterations in EGFR are among the most common driver mutations in lung cancer patients
Merck/Daiichi Sankyo’s ADC candidate shows promise in phase 3 lung cancer trial
EGFR-activating mutations occur in up to 38% of all NSCLC tumours globally
J&J’s Rybrevant combination shows positive overall survival trend in late-stage lung cancer study
Alterations in EGFR are among the most common driver mutations in NSCLC patients
J&J’s Rybrevant/Lazcluze combination approved by FDA as first-line lung cancer treatment
Non-small cell lung cancer accounts for up to 85% of all lung cancer cases
Johnson & Johnson’s Rybrevant recommended by CHMP for pre-treated advanced NSCLC
Non-small lung cancer accounts for up to 85% of all lung cancer cases
AstraZeneca’s Imfinzi regimen approved by MHRA to treat resectable lung cancer
The drug is now approved in Great Britain to treat both resectable and unresectable NSCLC